Century Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Century Therapeutics (IPSC) with a Buy rating and no price target Century develops potentially curative allogeneic stem cell therapies, the analyst tells investors in a research note. The firm says the company’s lead asset CNTY-813, an allogeneic insulin-expressing beta islet cell therapy for type 1 diabetes, has produced “intriguing” preclinical data. TD sees long-term shareholder value as Century’s pipeline advances.